| Literature DB >> 35343645 |
Hong Zhou1, Fangzhou Lou1, Jing Bai1, Yang Sun1, Wei Cai2, Libo Sun2, Zhenyao Xu1, Zhaoyuan Liu1, Lingyun Zhang1, Qianqian Yin2, Junxun Zhang2, Yuanyuan Gao2, Zhikai Wang2, Liman Niu2, Xiaojie Cai1, Siyu Deng1, Hong Wang2, Li Xia3, Florent Ginhoux2,4, Qun Li5, Honglin Wang1.
Abstract
Recent evidence has revealed that small polypeptides (containing fewer than 100 amino acids) can be translated from noncoding RNAs (ncRNAs), which are usually defined as RNA molecules that do not encode proteins. However, studies on functional products translated from primary transcripts of microRNA (pri-miRNA) are quite limited. Here, we describe a peptide termed miPEP31 that is encoded by pri-miRNA-31. miPEP31 is highly expressed in Foxp3+ regulatory T cells (Tregs ) and significantly promotes the differentiation of Tregs without affecting their inhibitory ability. Our results show that miPEP31 is a cell-penetrating peptide both in vitro and in vivo. miPEP31 downregulates miR-31 expression, enhances peripheral Treg induction, and dramatically suppresses experimental autoimmune encephalomyelitis. Mechanistically, we show that miPEP31 acts as a transcriptional repressor inhibiting the expression of miRNA-31, a negative regulator of Tregs . Our results reveal an indispensable role of miPEP31 in maintaining immune homeostasis by promoting Treg differentiation and also present a potential therapeutic peptide for modulating miRNA expression and treating autoimmune diseases.Entities:
Keywords: Treg; autoimmune disease; miPEP31; miR-31; transcriptional repressor
Mesh:
Substances:
Year: 2022 PMID: 35343645 PMCID: PMC9066071 DOI: 10.15252/embr.202153475
Source DB: PubMed Journal: EMBO Rep ISSN: 1469-221X Impact factor: 9.071